(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Since the advent of hybridoma technology more than two decades ago, numerous antibodies have entered the clinical setting as potent therapeutic agents. Their repeated application in humans, however, is limited by the development of human antimouse antibodies (HAMA) in the recipient, leading to allergic re- tions against the foreign murine protein and rapid neutralization. To circumvent these limitations many new antibodies have recently been tailored through recombinant antibody technology. The initial clinical data show encouraging results, thus demonstrating the potential of these new therapeutic agents. The purpose of Recombinant Antibodies for Cancer Therapy is to present a collection of detailed protocols in recombinant antibody technology. It is pri- rily addressed to scientists working on recombinant antibodies as well as cli- cians involved with antibody-based therapies. As with other volumes of this series, we placed the main focus on providing detailed protocols describing procedures step-by-step. Moreover, each protocol supplies a troubleshooting guide containing detailed information on possible problems and hints for pot- tial solutions. Antibody technology is a subject of constant and rapid change. This volume, therefore, does not attempt to cover all possible current experimental approaches in the field. Rather, we present carefully selected protocols, written by competent authors who have successfully verified the particular method described. Given our own professional backgrounds and interest in oncology, we chose to conc- trate chiefly on therapeutic agents for cancer patients.
Contents:
Part I. Introduction
Generation of Antibody Molecules Through Antibody Engineering
Sergey M. Kipriyanov
Application of Recombinant Antibodies in Cancer Patients
Jurgen Krauss, Michaela Arndt, and Michael Pfreundschuh
Part II. Hybridoma-Derived Antibodies
DNA Immunization as a Means to Generate Antibodies to Proteins
Partha S. Chowdhury
Chimerization of a Monoclonal Antibody for Treating Hodgkin's Lymphoma
Jurgen Krauss, Hans Heinrich Foerster, Barbara Uchanska-Ziegler, and Andreas Ziegler
Humanization of Monoclonal Antibodies by CDR Grafting
Siobhan O'Brien and Tarran Jones
Part III. Recombinant Antibody Fragments from Phagemid-Displayed Antibody Repertoires
Generation and Screening of a Modular Human scFv Expression Library from Mulitple Donors
Martin Welschof, Christiane Christ, Ingrid Hermes, Armin Keller, Christian Kleist, and Michael Braunagel
Construction of Semisynthetic Antibody Libraries
Michael Braunagel
Single-Domain VH Antibody Fragments from a Phage Display Library
Liat Binyamin, Daniel Plaksin, and Yoram Reiter
Isolation of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selection
Mariangela Figini, Andrew Green, Francesco Colotta, and Silvana Canevari
Human Recombinant Fab Antibodies with T-Cell Receptor-Like Specificities Generated from Phage Display Libraries
Jan Engberg, Ali F. Yenidunya, Rikke Clausen, Liselotte B. Jensen, Peter Sorensen, Pernille Kops, and Erik Riise
Engineering Hot Spots for Affinity Enhancement of Antibodies
Partha S. Chowdhury
Simultaneous Humanization and Affinity Optimization of Monoclonal Antibodies
Herren Wu
Tailoring Kinetics of Antibodies Using Focused Combinatorial Libraries
Herren Wu and Ling-Ling An
Part IV. Antibody Fragments with AdditionalProperties
Engineering scFvs for Improved Stability
Partha S. Chowdhury and George Vasmatzis
Recombinant Single-Chain and Disulfide-Stabilized Fv Immunotoxins for Cancer Therapy
Revital Niv, Dina Segal, and Yoram Reiter
Generation of Recombinant Immunotoxins for Specific Targeting of Tumor-Related Peptides Presented by MHC Molecules
Cyril J. Cohen, Galit Denkberg, Dina Segal, and Yoram Reiter
Construction and Characterization of RNase-Based Targeted Therapeutics
Dianne L. Newton, Junichiro Futami, Dale Ruby, and Susanna M. Rybak
Bispecific Diabodies for Cancer Therapy
Michaela Arndt and Jurgen Krauss
Generation and Characterization of Bispecific Tandem Diabodies for Tumor Therapy
Sergey M. Kipriyanov
Generation of Recombinant Multimeric Antibody Fragments for Tumor Diagnosis and Therapy
Barbara E. Power, Alexander A. Kortt, and Peter J. Hudson
Construction and Characterization of Minibodies for Imaging and Therapy of Colorectal Carcinomas
Paul J. Yazaki and Anna M. Wu
Generation, Expression, and Monitoring of Recombinant Immune Receptors for Use in Cellular Immunotherapy
Andreas Hombach, Claudia Heuser, and Hinrich Abken
Tailoring Natural Effector Functions: Antibody Engineering Beyond Humanization
Ole H. Brekke and John E. Thommesen
Single-Chain Fv-Based Affinity Purification of the Cellular Stress Protein gp96 for Vaccine Development
Christian Kleist, Daniele Arnold-Schild, Martin Welschof, Martina Finger, Gerhard Opelz, Hans-Georg Rammensee, Hansjoerg Schild, and Peter Terness
Recombinant Adenoviruses for In Vivo Expression of Antibody Fragments
Roland E. Kontermann, Tina Korn, and Valerie Jerome
Part V. Large Scale Production of Recombinant Antibodies for Clinical Application
Production of Antibody Fragments in a Bioreactor
Halldis
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: October, 2011
Pages: 498
Weight: 753g
Availability: Available
Subcategories: Oncology
From the same series
